Hakan Edstrom steps down as CEO of MannKind Corporation

MannKind Corporation has announced the resignation of Hakan Edstrom, who was the company’s President and CEO, as well as a director. In the wake of the resignation, Alfred Mann has been appointed interim CEO, effective November 19, 2015, and a board committee has begun a search for a new CEO.

Edstrom took over as CEO from Mann in January 2015, prior to Sanofi’s launch of MannKind’s Afrezza inhaled insulin, which took place in early February.

Net sales of Afrezza were €2 million for the 3rd quarter of 2015 and €5 million for the first 9 months of the year, according to Sanofi.

Read the MannKind press release.